NEW YORK (GenomeWeb News) - Dennis Gilbert has resigned as chief scientific officer and vice president of research at Applied Biosystems, according to an ABI spokesman who confirmed via e-mail that Gilbert left the company as of Aug. 1 to “pursue other career interests.”
Lubert Stryer, a professor of cell biology at Stanford University and chairman of Affymetrix’s scientific advisory board, was awarded the 2006 National Medal of Science in a ceremony at the White House on July 27. Stryer won the award for “his many contributions to molecular biology and biochemistry over the past four decades,” Affy said this week.
Stryer has “made many landmark contributions in fluorescence energy transfer, light-directed chemical synthesis, and vision research and signal transduction,” the company said. Stryer was also a co-author of “the first description of microarray technology” in Science in 1991.
Prodesse has named Ira Marks to its board of directors. Marks was a senior executive at Bio-Rad Laboratories, and over the years he has punched the clocks at Nanogen and Cepheid. Marks currently is GM of MiltenyiBiotec.
High Throughput Genomics has tapped Jerry Zemaitis to be vice president of commercial operations. In this new position, Zemaitis will handle strategic agreements and partnerships with businesses and with academic institutions.
Zemaitis previously was VP of sales at SeraCare and was involved in business development at Caliper Technologies and at Aclara BioSciences. He most recently was founder of Zeta Strategic Consulting.
Gene Logic named Stephen Donahue to be president of its clinical development division. Donahue will run the company’s proprietary drug candidates through repositioning partnerships, the company said. Donahue formerly was VP of clinical research and operations at Epix Pharmaceuticals and was medical director at Merck. He also was involved in clinical pharmaceutical development at Bristol-Meyers Squibb.
Nathan Yoganathan has shifted into a senior advisory role at Med BioGene. Yoganathan, the company’s founder and president, will quit his role as chief scientific officer to become chief scientific advisor.
Bradley McLean, a senior scientist at MBI, has been appointed to the newly opened CSO position. McLean has worked at Twinstrand Therapeutics and at InphoGene BioCommunications and was a post-doc fellow at the British Columbia Research Institute for Children’s and Women’s Health.
Alpha Innotech has elected Joseph Keegan and Gus Davis to be independent directors on the company’s board of directors. Keegan formerly was CEO of Molecular Devices. Davis was COO of BioSource International, and he held senior posts at Amersham and Pharmacia Biotechnology.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.